Stocks and InvestingStocks and Investing
Mon, February 28, 2022
Sun, February 27, 2022
Fri, February 25, 2022
Thu, February 24, 2022

Christopher Raymond Maintained (BMRN) at Buy with Increased Target to $125 on, Feb 24th, 2022


Published on 2024-10-27 19:49:45 - WOPRAI, Christopher Raymond
  Print publication without navigation


Christopher Raymond of Piper Sandler, Maintained "BioMarin Pharmaceutical Inc." (BMRN) at Buy with Increased Target from $121 to $125 on, Feb 24th, 2022.

Christopher has made no other calls on BMRN in the last 4 months.



There are 4 other peers that have a rating on BMRN. Out of the 4 peers that are also analyzing BMRN, 1 agrees with Christopher's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Matthew Harrison of "Morgan Stanley" Maintained at Hold with Increased Target to $90 on, Monday, November 22nd, 2021


These are the ratings of the 3 analyists that currently disagree with Christopher


  • Joseph Schwartz of "SVB Leerink" Maintained at Buy with Increased Target to $115 on, Monday, November 22nd, 2021
  • Tiago Fauth of "Credit Suisse" Maintained at Buy with Increased Target to $105 on, Monday, November 22nd, 2021
  • Tim Lugo of "William Blair" Upgraded from Hold to Buy on, Monday, November 22nd, 2021